IPO market continues to churn with a pair of Covid-19 biotechs seeking Nasdaq, while mitochondria-focused Reneo debuts
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Biotech continues to see a huge flow of companies looking to make their public debuts as the second quarter gets underway.
Two European biotechs working on Covid-19 vaccines, Vaccitech and Valneva, both filed their SEC paperwork over the weekend, while mitochondrial disease company Reneo Pharmaceuticals priced its own IPO last Friday. Per Endpoints News’ tally, the IPO count this year has now surpassed 40 biotechs that have priced or filed, roughly on pace to match 2020’s record of 92.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.